- Reuters•17 days ago
Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported a quarterly profit that beat analysts' estimates, helped by its exclusive launch of the first generic version of leukaemia drug Gleevec in the United States. Net profit for the April-June quarter was 20.34 billion rupees ($304.17 million). Sun had reported a profit of 5.56 billion rupees a year ago, hurt by a big charge related to remediation costs at its drug factories.
- Bloomberg•17 days ago
Sun Pharmaceutical Industries Ltd. reported quarterly profit that more than tripled from a year earlier as its exclusive right to sell the generic version of Novartis AG’s blockbuster cancer drug Gleevec ...
- Business Wire•21 days ago
As part of the company’s philosophy of putting patients' interests first, Sun Pharma announced the extension of its Imatinib Mesylate Savings Card Program beyond July 31, 2016.
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
NSE - NSE Delayed Price. Currency in INR
|Day's Range||746.60 - 760.90|
|52wk Range||704.00 - 933.95|
|1y Target Est||N/A|
|P/E Ratio (ttm)||29.54|
|Avg Vol (3m)||3,682,921|
|Dividend & Yield||N/A (N/A)|